Skip to content

Clinical trials

Phase 2 Neurodegenerative Diseases trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Neurodegenerative Diseases Phase: Phase 2 Country / region: United States Clear all

37 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20071
20082
20092
20102
20131
20161
20177
20181
20191
20202
20212
20223
20233
20241
20253
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed20
Active, not recruiting6
Terminated4
Recruiting3
Enrolling by invitation2
Withdrawn2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Alkahest, Inc.3
Alterity Therapeutics2
Flex Pharma, Inc.2
MapLight Therapeutics2
National Institute of Neurological Disorders and Stroke (NINDS)2
Novartis2
Novartis Pharmaceuticals2
AbbVie1
Amylyx Pharmaceuticals Inc.1
Andrew Newberg1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Neurodegenerative Diseases37
Central Nervous System Diseases18
Nervous System Diseases17
Alzheimer Disease15
Brain Diseases13
Dementia11
Parkinson Disease10
Movement Disorders8
Neurocognitive Disorders8
Mental Disorders7

Trials

Showing 1 to 25 of 37. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.